KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Restructuring Costs: 2009-2017

Historic Restructuring Costs for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Sep 2017 value amounting to $550,000.0 billion.

  • Teva Pharmaceutical Industries' Restructuring Costs rose 234.15% to $550,000.0 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $969,000.5 billion, marking a year-over-year increase of 220.86%. This contributed to the annual value of $699.0 million for FY2016, which is 38.20% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Restructuring Costs stood at $550,000.0 billion for Q3 2017, which was up 31.26% from $419,000.0 billion recorded in Q2 2017.
  • Teva Pharmaceutical Industries' Restructuring Costs' 5-year high stood at $712,000.0 billion during Q2 2016, with a 5-year trough of -$410,000.0 billion in Q3 2016.
  • For the 3-year period, Teva Pharmaceutical Industries' Restructuring Costs averaged around $115,545.6 billion, with its median value being $285.0 million (2015).
  • Data for Teva Pharmaceutical Industries' Restructuring Costs shows a peak YoY increase of 249,824,461.40% (in 2016) and a maximum YoY decrease of 106,770,933.33% (in 2016) over the last 5 years.
  • Teva Pharmaceutical Industries' Restructuring Costs (Quarterly) stood at $460.0 million in 2013, then slumped by 37.83% to $286.0 million in 2014, then crashed by 43.01% to $163.0 million in 2015, then spiked by 70.55% to $278.0 million in 2016, then surged by 234.15% to $550,000.0 billion in 2017.
  • Its Restructuring Costs stands at $550,000.0 billion for Q3 2017, versus $419,000.0 billion for Q2 2017 and $240.0 million for Q1 2017.